1349709-01-8

Basic information

• Product Name: 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine
• Synonyms: 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine;2-Cyclobutyl-5-methyl-2H-pyrazol-3-ylamine
• CAS NO: 1349709-01-8
• Molecular Formula: C₈H₁₃N₃
• Molecular Weight: 151.20892
• Mol File: 1349709-01-8.mol

Chemical Properties

• Boiling Point: 306.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• PKA: 5.13±0.12(Predicted)
• CAS DataBase Reference: 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine(1349709-01-8)
• EPA Substance Registry System: 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine(1349709-01-8)

Safety Data

• Hazardous Substances Data: 1349709-01-8(Hazardous Substances Data)

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 1156980-49-2 cyclobutyl hydrazine hydrochloride 
• 870-64-4 2-aminocrotononitrile 

Relevant articles and documents

Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

The G protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5-yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent Kp > 0.6).

9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

AZAINDAZOLES

Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.